CoChat
Sign Up
Cited by 128Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort

Open access
Tariot, Pierre N., Lopera, Francisco, Langbaum, Jessica B., Thomas, Ronald G., Hendrix, Suzanne, Schneider, Lon S., Rios‐Romenets, Silvia, Giraldo, Margarita, Acosta, Natalia, Tobon, Carlos, Ramos, Claudia, Espinosa, Alejandro, Cho, William, Ward, Michael, Clayton, David, Friesenhahn, Michael, Mackey, Howard, Honigberg, Lee, Sanabria Bohorquez, Sandra, Chen, Kewei, Walsh, Trisha, Langlois, Carolyn, Reiman, Eric M., Alzheimer's Prevention Initiative·2018·Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI 10.1016/j.trci.2018.02.002PMC PMC6021543
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: Autosomal‐dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is, who have “preclinical” AD. Crenezumab is an antiamyloid monoclonal antibody that binds monomeric and aggregated forms of amyloid β, with highest affinity for oligomers; it is in development for early stages of sporadic AD and for ADAD. Methods: This is a prospective, randomized, double‐blind, placebo‐controlled phase 2 study of the efficacy of crenezumab versus placebo in asymptomatic PSEN1 E280A mutation carriers from family kindreds with ADAD in Colombia. Participants were randomized to receive either crenezumab or placebo for 260 weeks. The study was designed to enroll a planned total of 300 participants, including 200 preclinical mutation carriers (approximately 100 treatment, 100 placebo) and an additional control group of mutation noncarriers from the same family kindreds included to mask mutation carrier status (100 placebo only). The primary outcome is change in the Alzheimer's Prevention Initiative ADAD Composite Cognitive Test Score from baseline to week 260. Secondary outcomes include time to progression to mild cognitive impairment due to AD or dementia due to AD; changes in dementia severity, memory, and overall neurocognitive functioning; and changes in amyloid–positron emission tomography, fluorodeoxyglucose–positron emission tomography, magnetic resonance imaging volumes, and cerebrospinal fluid levels of β amyloid, tau, and p‐tau. Safety and tolerability are assessed. Results: Two hundred fifty‐two participants were enrolled between December 2013 and February 2017. Discussion: We describe the first large‐scale, potentially label‐enabling clinical trial of a preclinical treatment for ADAD. Results from this trial will inform on the efficacy of crenezumab for delaying onset of, slowing decline in, or preventing cognitive impairment in individuals with preclinical ADAD and will foster an improved understanding of AD biomarkers and their relationship to clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trci.2018.02.002

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 65 references

Research works printed but not linked: 3

  1. Salloway S., 2014, Amyloid PET imaging results from a study to evaluate the impact of crenezumab on fibrillar amyloid in patients with mild‐to‐moderate Alzheimer's disease., J Prev Alz, 1, 214
  2. Reiman E.M., 2014, Analysis of amyloid‐β PET changes from the crenezumab anti‐Aβ phase 2 trial using a pre‐specified cerebral white matter reference region‐of‐interest., J Prev Alz, 1, 214
  3. Sheikh J.I., 1986, Clinical Gerontology: A Guide to Assessment and Intervention, 165

Cited by

Sorted by citations

Items 101–128 of 128

Related

See all

Metadata

Authors
Tariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., Ramos, C., Espinosa, A., Cho, W., Ward, M., Clayton, D., Friesenhahn, M., Mackey, H., Honigberg, L., Sanabria Bohorquez, S., Chen, K., Walsh, T., Langlois, C., Reiman, E. M., & Initiative, A. P.
Affiliations
  • Banner Alzheimer’s Institute (US)
  • Universidad de Antioquia (CO)
  • University of California San Diego (US)
  • Pentara Corporation Salt Lake City UT USA
  • University of Southern California (US)
  • Grupo de Neurociencias Universidad de Antioquia, SIU Medellín Colombia
  • Genentech, a Member of the Roche Group South San Francisco CA USA
  • Genentech (US)
Corresponding author
Tariot, Pierre N.
ORCID
Venue
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher
Wiley
Published
2018-01
Volume
4
Issue
1
Pages
150-160
ISSN
2352-8737 (ISSN-L)
DOI
10.1016/j.trci.2018.02.002
PMC
PMC6021543
OpenAlex
W2789516300
Cited by
128
References
65
Citations by year
2026: 1 · 2025: 9 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 32 · 2019: 20 · 2018: 7
FWCI
13.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Repositorio Digital - Academia Colombiana de Ciencias Exactas, Fisicas y Naturales (submittedVersion, other-oa)
Funders
  • National Institute on Aging (1RFAG041705‐01A1)
  • NOMIS Stiftung
  • Flinn Foundation (1862)
  • AstraZeneca
  • H. Lundbeck A/S
  • Merck
  • Roche
  • Amgen
  • Biogen
  • Elan
  • GE Healthcare
  • Genentech
  • Novartis
  • Arizona Department of Health Services
  • Foundation for Biomedical Research and Innovation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
autosomal dominant Alzheimer's disease, crenezumab, preclinical Alzheimer's disease, PSEN1 E280A mutation, amyloid-beta oligomers, anti-amyloid monoclonal antibodies, cognitive decline prevention, amyloid PET, cerebrospinal fluid biomarkers, tau protein, familial kindred, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review